Ginkgo Bioworks (DNA) vs SL Science (SLBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Ginkgo Bioworks (DNA) has outperformed SL Science (SLBT) over the past year, losing 22.6% versus a loss of 85.4%. SL Science is the larger company by market cap ($858.0 million vs $749.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | SLBT |
|---|---|---|
| Share price | $11.14 | $1.53 |
| Market cap | $749.83M | $857.96M |
| 1-day change | -2.92% | +1.32% |
| YTD return | +38.03% | -85.68% |
| 1-year return | -22.60% | -85.42% |
| 5-year return | -97.59% | — |
| EPS (TTM) | $-5.06 | $-0.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.22 | $14.50 |
| 52-week low | $5.37 | $1.42 |
| Distance from 52-week high | -38.89% | -89.45% |
| Analyst consensus | none | — |
| Avg. price target upside | -37.14% | — |
| Average volume | 1.77M | 80.93K |
| Shares outstanding | 55.38M | 560.76M |
| Employees | 485 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNA has outperformed SLBT by 62.8 percentage points over the past year.
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
About SL Science
SLBT stock →SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
DNA vs SLBT FAQ
Which is bigger, Ginkgo Bioworks or SL Science?
SL Science (SLBT) is larger, with a market capitalization of $857.96M compared with $749.83M for Ginkgo Bioworks (DNA).
Which stock has performed better over the past year, DNA or SLBT?
DNA returned -22.60% over the past 12 months, compared with -85.42% for SLBT (price return, excluding dividends). Past performance does not predict future results.
Are Ginkgo Bioworks and SL Science in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.